OBI Pharma, Inc
OBI Pharma, Inc
Explore linked clinical trials.4 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors | Advanced Solid Tumor | Recruiting | Phase 1 / Phase 2 | 2026-01-05 | NCT07124117 | |
| A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors | Advanced Solid Tumor | Active, not recruiting | Phase 1 / Phase 2 | 2025-08-08 | NCT06480240 | |
| To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2025-08-03 | NCT05442060 | |
| Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 3 | 2025-05-09 | NCT03562637 |